Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has received $1.4 million in tax rebate incentives under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme, which is designed to help companies innovate and grow by offsetting some costs of eligible research and development.
The company intends to use the funding to develop its ADAPT®, DurAVR™ and ComASUR™ technologies.
Anteris recently made strides with its DurAVR THV technology, the world’s only balloon-expandable, single-piece transcatheter aortic valve (TAVR) for the treatment of aortic stenosis with a second successful implant procedure.
Read: Anteris Technologies lauds second successful implant procedure for innovative transcatheter aortic valve
The technology was implanted in a Valve-in-Valve (ViV) procedure as part of Health Canada’s Special Access Program (SAP).
A ViV procedure is used for patients in life-threatening situations, when their current bioprosthetic aortic valve is failing due to calcification or structural deterioration, and a new heart valve must be implanted inside the failing valve.
Structural heart technology
Apart from its lead product DurAVR, AVR is developing ADAPT tissue and the ComASUR Delivery System.
ADAPT isAnteris’ patented anti-calcification tissue technology, which has been used clinically for over 10 years and distributed for use in more than 50,000 patients worldwide.
The company designed the ComASUR delivery system to provide controlled deployment and accurate placement of the DurAVR THV with balloon-expandable delivery, allowing precise alignment with the heart’s native junctions to achieve optimal valve positioning.
The company believes its technology will revolutionise the structural heart market by “delivering clinically superior solutions for significant unmet clinical needs.”